

## COMPANY OVERVIEW

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company seeking to discover and develop novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. We have identified promising preclinical and early clinical stage antiviral therapeutics that target the replication process of influenza virus, SARS-CoV-2 virus, hepatitis C virus, and norovirus.

## RECENT NEWS

### Cocrystal Pharma to Present Data from its Oral and Intranasal COVID-19 Therapeutics Programs at the World Antiviral Congress 2021

Oct 21 2021, 8:00 AM EDT

### Cocrystal Pharma to Present at the Dawson James 2021 Small Cap Growth Conference on October 21, 2021

Oct 14 2021, 8:00 AM EDT

### Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza

Oct 6 2021, 8:49 AM EDT

## STOCK OVERVIEW

|               |         |
|---------------|---------|
| Symbol        | COCP    |
| Exchange      | Nasdaq  |
| Market Cap    |         |
| Last Price    | \$      |
| 52-Week Range | \$ - \$ |

## INVESTOR RELATIONS

LHA Investor Relations  
Jody Cain  
T: 310-691-7100  
[jcain@lhai.com](mailto:jcain@lhai.com)

## MANAGEMENT TEAM

### Sam Lee, Ph.D.

Interim Co-Chief Executive Officer and President

### James J. Martin

Interim Co-Chief Executive Officer and Chief Financial Officer

## COCRYSTAL PHARMA, INC.

19805 North Creek Parkway  
Bothell, WA 98011  
US

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.